Cargando…
157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response
Autores principales: | VanDevanter, D., Heltshe, S., Skalland, M., West, N., Sanders, D., Goss, C., Flume, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Cystic Fibrosis Society.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518450/ http://dx.doi.org/10.1016/S1569-1993(21)01582-4 |
Ejemplares similares
-
510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study
por: Thornton, C., et al.
Publicado: (2022) -
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
por: VanDevanter, Donald R, et al.
Publicado: (2010) -
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
por: VanDevanter, Donald R., et al.
Publicado: (2021) -
Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019) -
C-Reactive Protein (CRP): A poor prognostic biomarker in COVID-19
por: Bouayed, Mohamed Zakaria, et al.
Publicado: (2022)